Opko Health Inc. (OPK)
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.09 per share a year ago.
OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisors IR Dr. Phillip Frost - Chairman and CEO Dr. Elias Zerhouni - Vice Chairman and President Adam Logal - Chief Financial Officer Gary Nabel - Chief Innovation Officer Conference Call Participants Maury Raycroft - Jefferies Jeffrey Cohen - Ladenburg Thalmann Edward Tenthoff - Piper Sandler Yale Jen - Laidlaw and Company Eduardo Martinez-Montes - H.C. Wainwright Operator Good day.
Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call.
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago.
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
